OBJECTIVE: Adiponectin, a protein secreted by adipose cells, is inversely associated with endometrial cancer. Our objective was to assess prediagnostic adiponectin levels in relation to risk of endometrial cancer. STUDY DESIGN: This was a prospective nested case-control study within the Nurses' Health Study with 146 cases and 377 controls. Adiponectin was measured using enzyme-linked immunosorbent assay. Logistic regression analyses were performed adjusting for known endometrial cancer risk factors. RESULTS: Mean age at diagnosis was 64.6 years. Mean interval between blood draw and diagnosis was 7.4 years (range, 2-13). There was no difference in median adiponectin (cases 12.9 vs controls 12.9 μg/mL; P = .97). Adiponectin >15 μg/mL was not associated with endometrial cancer risk (relative risk = 0.86; 95% confidence interval, 0.53-1.39; P = .48), even among postmenopausal women (odds ratio, 0.66; 95% confidence interval, 0.29-1.5). Results did not vary by time from blood draw to diagnosis (P for heterogeneity = .18). CONCLUSION: Prediagnostic adiponectin was not predictive of endometrial cancer risk. Further study will better define the relationship between adiponectin and endometrial cancer.
OBJECTIVE:Adiponectin, a protein secreted by adipose cells, is inversely associated with endometrial cancer. Our objective was to assess prediagnostic adiponectin levels in relation to risk of endometrial cancer. STUDY DESIGN: This was a prospective nested case-control study within the Nurses' Health Study with 146 cases and 377 controls. Adiponectin was measured using enzyme-linked immunosorbent assay. Logistic regression analyses were performed adjusting for known endometrial cancer risk factors. RESULTS: Mean age at diagnosis was 64.6 years. Mean interval between blood draw and diagnosis was 7.4 years (range, 2-13). There was no difference in median adiponectin (cases 12.9 vs controls 12.9 μg/mL; P = .97). Adiponectin >15 μg/mL was not associated with endometrial cancer risk (relative risk = 0.86; 95% confidence interval, 0.53-1.39; P = .48), even among postmenopausal women (odds ratio, 0.66; 95% confidence interval, 0.29-1.5). Results did not vary by time from blood draw to diagnosis (P for heterogeneity = .18). CONCLUSION: Prediagnostic adiponectin was not predictive of endometrial cancer risk. Further study will better define the relationship between adiponectin and endometrial cancer.
Authors: L A Brinton; M L Berman; R Mortel; L B Twiggs; R J Barrett; G D Wilbanks; L Lannom; R N Hoover Journal: Am J Obstet Gynecol Date: 1992-11 Impact factor: 8.661
Authors: S E Hankinson; W C Willett; J E Manson; G A Colditz; D J Hunter; D Spiegelman; R L Barbieri; F E Speizer Journal: J Natl Cancer Inst Date: 1998-09-02 Impact factor: 13.506
Authors: K Maeda; K Okubo; I Shimomura; T Funahashi; Y Matsuzawa; K Matsubara Journal: Biochem Biophys Res Commun Date: 1996-04-16 Impact factor: 3.575
Authors: C Weyer; T Funahashi; S Tanaka; K Hotta; Y Matsuzawa; R E Pratley; P A Tataranni Journal: J Clin Endocrinol Metab Date: 2001-05 Impact factor: 5.958
Authors: S E Hankinson; W C Willett; J E Manson; D J Hunter; G A Colditz; M J Stampfer; C Longcope; F E Speizer Journal: J Natl Cancer Inst Date: 1995-09-06 Impact factor: 13.506
Authors: Mia M Gaudet; Roni T Falk; Robert D Stevens; Marc J Gunter; James R Bain; Ruth M Pfeiffer; Nancy Potischman; Jolanta Lissowska; Beata Peplonska; Louise A Brinton; Montserrat Garcia-Closas; Christopher B Newgard; Mark E Sherman Journal: J Clin Endocrinol Metab Date: 2012-06-22 Impact factor: 5.958
Authors: Britton Trabert; Ronald C Eldridge; Ruth M Pfeiffer; Meredith S Shiels; Troy J Kemp; Chantal Guillemette; Patricia Hartge; Mark E Sherman; Louise A Brinton; Amanda Black; Anil K Chaturvedi; Allan Hildesheim; Sonja I Berndt; Mahboobeh Safaeian; Ligia Pinto; Nicolas Wentzensen Journal: Int J Cancer Date: 2016-11-07 Impact factor: 7.396
Authors: Cher M Dallal; Louise A Brinton; Douglas C Bauer; Diana S M Buist; Jane A Cauley; Trisha F Hue; Andrea Lacroix; Jeffrey A Tice; Victoria M Chia; Roni Falk; Ruth Pfeiffer; Michael Pollak; Timothy D Veenstra; Xia Xu; James V Lacey Journal: Endocr Relat Cancer Date: 2013-02-18 Impact factor: 5.678
Authors: Patricia Luhn; Cher M Dallal; Jocelyn M Weiss; Amanda Black; Wen-Yi Huang; James V Lacey; Richard B Hayes; Frank Z Stanczyk; Nicolas Wentzensen; Louise A Brinton Journal: Cancer Epidemiol Biomarkers Prev Date: 2013-05-21 Impact factor: 4.254
Authors: Christine M Friedenreich; Annie R Langley; Thomas P Speidel; David C W Lau; Kerry S Courneya; Ilona Csizmadi; Anthony M Magliocco; Yutaka Yasui; Linda S Cook Journal: Endocr Relat Cancer Date: 2012-11-09 Impact factor: 5.678